Phase I/II Study of Intrathecal Administration of Recombinant Human Hepatocyte Growth Factor in Patients with Acute Spinal Cord Injury: A Double-Blind, Randomized Clinical Trial of Safety and Efficacy
Authors:
- Narihito NagoshiNNNarihito Nagoshi
- Osahiko TsujiOTOsahiko Tsuji
- Kazuya KitamuraKKKazuya Kitamura
- Kota SudaKSKota Suda
- Takeshi MaedaTMTakeshi Maeda
- Yoshiyuki YatoYYYoshiyuki Yato
- Takayuki AbeTATakayuki Abe
- Daichika HayataDHDaichika Hayata
- Morio MatsumotoMMMorio Matsumoto
- Hideyuki OkanoHideyuki Okano
- Masaya NakamuraMNMasaya Nakamura
Open Access
- 6 July 2020
- journal article
- research article
- Published by SAGE Publications in Journal of Neurotrauma
- Vol. 37 (15) , 1752-1758
Abstract
Spinal cord injury (SCI) is an abrupt traumatic injury that leads to permanent functional loss, and no practical treatment is available. We have developed pharmaceutical recombinant human hepatocyte growth factor (KP-100), and its efficacy for SCI has been verified using animal models. The purpose of this study was to evaluate the safety and efficacy of intrathecal KP-100 administration for SCI patients in the acute phase. This investigation was a multi-center, randomized, double-blind study. Subjects with modified Frankel grade A/B1/B2 at 72 h after SCI were included. KP-100 was administered intrathecally. Subjects were followed up for 168 days after the first administration. Outcomes were evaluated using American Spinal Injury Association (ASIA) scores and subjected to analysis of covariance. Our results demonstrated that the subjects did not show any serious adverse events caused by KP-100. Forty-three subjects underwent neurological function testing (26 in KP-100 group; 17 in placebo group), which revealed that KP-100 contributed to motor improvement at Days 140 ( p = 0.050) and 168 ( p = 0.079). In the subset of subjects with Frankel grade A, the proportions of subjects who gained at least 1 point on their lower-extremity motor scores were 33.3% (5/15) and 6.3% (1/16) in the KP-100 and placebo groups, respectively ( p = 0.083). Therefore, KP-100 has the potential to be useful and beneficial for SCI patients during the acute phase. However, this was a phase I/II trial and did not definitely address the question of efficacy; a larger phase III trial would be required to assess the efficacy.Keywords
This publication has 27 references indexed in Scilit:
- Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injuryBrain, 2012
- Human Hepatocyte Growth Factor Promotes Functional Recovery in Primates after Spinal Cord InjuryPLOS ONE, 2011
- Hepatocyte growth factor promotes endogenous repair and functional recovery after spinal cord injuryJournal of Neuroscience Research, 2007
- Hepatocyte growth factor improved learning and memory dysfunction of microsphere‐embolized ratsJournal of Neuroscience Research, 2004
- Prediction of Prognosis Using Modified Frankel Classification in Cervical Spinal Cord Injured Patients.Rihabiriteishon igaku, 2001
- Brain-Derived Neurotrophic Factor Stimulates Hindlimb Stepping and Sprouting of Cholinergic Fibers after Spinal Cord InjuryExperimental Neurology, 1998
- Nerve Growth Factor Delivery by Gene Transfer Induces Differential Outgrowth of Sensory, Motor, and Noradrenergic Neurites after Adult Spinal Cord InjuryExperimental Neurology, 1996
- Hepatocyte Growth Factor and Its Variant with a Deletion of Five Amino Acids Are Distinguishable in Their Biological Activity and Tertiary StructureBiochemical and Biophysical Research Communications, 1994
- Molecular cloning and expression of human hepatocyte growth factorNature, 1989
- The value of postural reduction in the initial management of closed injuries of the spine with paraplegia and tetraplegiaSpinal Cord, 1969